SPRC

SciSparc Ltd.

7.17 USD

Last updated Dec 6, 04:47 UTC

Yesterday HIGH

$8.39

Yesterday LOW

$7.15

52w HIGH

$34.55

52w LOW

$2.8

EPS

1

PE

7.17

Next Earnings

Dec 19, 2023

Overview News Government Trades

SciSparc Ltd. stock is up 14.54% since 30 days ago. The next earnings date is Dec 19, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November.

SciSparc Ltd. develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation. SCi-160 for the. treatment of pain; SCII-210 for the. treatment of autism spectrum disorder and epilepsy. The company was formerly known as Therapix Biosciences.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

scisparc.com

Benzinga Newsdesk

Wed Nov 15, 2023

SciSparc Shares Resume Trade
Benzinga Newsdesk

Wed Nov 15, 2023

SciSparc Shares Halted On Circuit Breaker To The Downside, Stock Now Up 67.4%
ryanfaloona@benzinga.com

Wed Nov 15, 2023

Market-Moving News for November 15th

SPRC: 106% | SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation KNTE: 54% | Foresite Capital Fund In Amended 13D Filing
Benzinga Newsdesk

Wed Nov 15, 2023

SciSparc Says 'trial results indicated that SciSparc's proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients who participated.'
Benzinga Newsdesk

Wed Nov 15, 2023

SciSparc Unveiled Results From Its Investigator-initiated Phase IIa Trial At The Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center
Nicolás Jose Rodriguez

Mon Nov 13, 2023

FDA-Approved Synthetic THC Trials Show 21% Tic Reduction In Tourette Syndrome Patients

SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, reported a new Phase IIb trial of SCI-110, a proprietary THC-based medication for Tourette Syndrome (TS) treatment.
Benzinga Newsdesk

Fri Nov 10, 2023

SciSparc Aims To Change Tourette Syndrome Treatments; Will Start A Phase IIb Trial With Its Innovative Pharma-Grade THC-Based Medication

SciSparc to conduct trial at Yale University in the USA, Tel Aviv Sourasky Medical Center in Israel and the Hannover Medical School in Germany
Lisa Levin

Tue Oct 31, 2023

Dow Gains 50 Points; Global Payments Posts Upbeat Earnings

U.S. stocks turned higher toward the end of trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.15% to 32,978.85 while the NASDAQ rose 0.20% to 12,814.52. The S&P 500 also rose, gaining, 0.38% to 4,182.85.
Lisa Levin

Tue Oct 31, 2023

Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment.
Lisa Levin

Tue Oct 31, 2023

Crude Oil Edges Higher; Caterpillar Earnings Top Views

U.S. stocks edged lower midway through trading, with the S&P 500 trading slightly lower on Tuesday. The Dow traded down 0.11% to 32,892.75 while the NASDAQ fell 0.23% to 12,760.61. The S&P 500 also fell, dropping, 0.01% to 4,166.81.